<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35311524</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>06</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1098-6596</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>66</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>19</Day>
            </PubDate>
          </JournalIssue>
          <Title>Antimicrobial agents and chemotherapy</Title>
          <ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E.</ArticleTitle>
        <Pagination>
          <StartPage>e0173221</StartPage>
          <MedlinePgn>e0173221</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e01732-21</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/aac.01732-21</ELocationID>
        <Abstract>
          <AbstractText>Botulism is a rare, life-threatening paralytic disease caused by botulinum neurotoxin (BoNT). Available treatments including an equine antitoxin and human immune globulin are given postexposure and challenging to produce and administer. NTM-1633 is an equimolar mixture of 3 human IgG monoclonal antibodies, E1, E2, and E3, targeting BoNT serotype E (BoNT/E). This first-in-human study assessed the safety, tolerability, pharmacokinetics (PK), and immunogenicity of NTM-1633. This double-blind, single-center, placebo-controlled dose escalation study randomized 3 cohorts of healthy volunteers to receive a single intravenous dose of NTM-1633 (0.033, 0.165, or 0.330 mg/kg) or saline placebo. Safety monitoring included physical examinations, clinical laboratory studies, and vital signs. Blood sampling was performed at prespecified time points for PK and immunogenicity analyses. Twenty-four subjects received study product (18 NTM-1633; 6 placebo), and no deaths were reported. An unrelated serious adverse event was reported in a placebo subject. Adverse events in the NTM-1633 groups were generally mild and similar in frequency and severity to the placebo group, and no safety signal was identified. NTM-1633 has a favorable PK profile with a half-life &gt;10 days for the 0.330 mg/kg dose and an approximately linear relationship with respect to maximum concentration and area under the concentration-time curve (AUC<sub>0→t</sub>). NTM-1633 also demonstrated low immunogenicity. NTM-1633 is well tolerated at the administered doses. The favorable safety, PK, and immunogenicity profile supports further development as a treatment for BoNT/E intoxication and postexposure prophylaxis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Raja</LastName>
            <ForeName>S M</ForeName>
            <Initials>SM</Initials>
            <Identifier Source="ORCID">0000-0003-0216-1564</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guptill</LastName>
            <ForeName>J T</ForeName>
            <Initials>JT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Duke Clinical Research Institute, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Juel</LastName>
            <ForeName>V C</ForeName>
            <Initials>VC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walter</LastName>
            <ForeName>E B</ForeName>
            <Initials>EB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Duke Human Vaccine Institute, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cohen-Wolkowiez</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Duke Clinical Research Institute, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hill</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>The EMMES Corporation, Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sendra</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>The EMMES Corporation, Rockville, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hauser</LastName>
            <ForeName>B</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jackson</LastName>
            <ForeName>P</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Duke Human Vaccine Institute, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tomic</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Ology Bioservices Incorporated, Alameda, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Espinoza</LastName>
            <ForeName>Y</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Ology Bioservices Incorporated, Alameda, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Swamy</LastName>
            <ForeName>G K</ForeName>
            <Initials>GK</Initials>
            <Identifier Source="ORCID">0000-0001-5092-6993</Identifier>
            <AffiliationInfo>
              <Affiliation>Duke Human Vaccine Institute, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Duke Universitygrid.26009.3d School of Medicine, Durham, North Carolina, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>K23 NS085049</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>UL1 TR002553</GrantID>
            <Acronym>TR</Acronym>
            <Agency>NCATS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HHSN272201500002C</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HHSN272201300017C</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>HHSN272201300017I</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Antimicrob Agents Chemother</MedlineTA>
        <NlmUniqueID>0315061</NlmUniqueID>
        <ISSNLinking>0066-4804</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.69</RegistryNumber>
          <NameOfSubstance UI="D001905">Botulinum Toxins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>T579M564JY</RegistryNumber>
          <NameOfSubstance UI="C096326">botulinum toxin type E</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001905" MajorTopicYN="Y">Botulinum Toxins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001906" MajorTopicYN="Y">Botulism</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006736" MajorTopicYN="N">Horses</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Clostridium botulinum</Keyword>
        <Keyword MajorTopicYN="Y">clinical trials</Keyword>
        <Keyword MajorTopicYN="Y">monoclonal antibodies</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare a conflict of interest. G.K.S. has been an investigator for clinical trials sponsored by Novavax, GlaxoSmithKline, and Regeneron and is currently an investigator for a clinical trial sponsored by Pfizer. She serves as Chair of Independent Data Monitoring Committees for GlaxoSmithKline and Pfizer. E.B.W. is a principal investigator for a study funded by Pfizer and is a co-investigator for a study funded by Moderna, and a member of an advisory board for Vaxcyte.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>9</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>12</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35311524</ArticleId>
        <ArticleId IdType="pmc">PMC9017376</ArticleId>
        <ArticleId IdType="doi">10.1128/aac.01732-21</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lamanna C. 1959. The most poisonous poison. Science
130:763–772. 10.1126/science.130.3378.763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.130.3378.763</ArticleId>
            <ArticleId IdType="pubmed">14413547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossetto O, Montecucco C. 2019. Tables of toxicity of botulinum and tetanus neurotoxins. Toxins
11:686. 10.3390/toxins11120686.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11120686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan Y, Barash JR, Conrad F, Lou J, Tam C, Cheng LW, Arnon SS, Marks JD. 2019. The novel clostridial neurotoxin produced by strain IBCA10-7060 is immunologically equivalent to BoNT/HA. Toxins
12:9. 10.3390/toxins12010009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins12010009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. 2019. Botulism annual summary, 2017.
Department of Health and Human Services, CDC, Atlanta, Georgia.</Citation>
        </Reference>
        <Reference>
          <Citation>Peak CM, Rosen H, Kamali A, Poe A, Shahkarami M, Kimura AC, Jain S, McDonald E. 2019. Wound botulism outbreak among persons who use black tar heroin—San Diego County, California, 2017–2018. MMWR Morb Mortal Wkly Rep
67:1415–1418. 10.15585/mmwr.mm675152a3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15585/mmwr.mm675152a3</ArticleId>
            <ArticleId IdType="pmc">PMC6334826</ArticleId>
            <ArticleId IdType="pubmed">30605447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yiannakopoulou E. 2015. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology
95:65–69. 10.1159/000370245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000370245</ArticleId>
            <ArticleId IdType="pubmed">25613637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K, Working Group on Civilian Biodefense. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA
285:1059–1070. 10.1001/jama.285.8.1059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.285.8.1059</ArticleId>
            <ArticleId IdType="pubmed">11209178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adalja AA, Toner E, Inglesby TV. 2015. Management of potential bioterrorism-related conditions. N Engl J Med
372:2272–2273. 10.1056/NEJMc1504248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1504248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centers for Disease Control and Prevention. 2010. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep
59:299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20300057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. 2006. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med
354:462–471. 10.1056/NEJMoa051926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa051926</ArticleId>
            <ArticleId IdType="pubmed">16452558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai S, Singh BR. 2007. Strategies to design inhibitors of Clostridium botulinum neurotoxins. Infect Disord Drug Targets
7:47–57. 10.2174/187152607780090667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/187152607780090667</ArticleId>
            <ArticleId IdType="pubmed">17346211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiris E, Burnett JC, Kane CD, Bavari S. 2014. Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem
14:2044–2061. 10.2174/1568026614666141022093350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1568026614666141022093350</ArticleId>
            <ArticleId IdType="pubmed">25335887</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Olson ME, Eubanks LM, Janda KD. 2019. Strategies to counteract botulinum neurotoxin A: nature's deadliest biomolecule. Acc Chem Res
52:2322–2331. 10.1021/acs.accounts.9b00261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.accounts.9b00261</ArticleId>
            <ArticleId IdType="pmc">PMC7478247</ArticleId>
            <ArticleId IdType="pubmed">31322847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bradford AB, Machamer JB, Russo TM, McNutt PM. 2018. 3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms. Toxicol Appl Pharmacol
341:77–86. 10.1016/j.taap.2018.01.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.taap.2018.01.012</ArticleId>
            <ArticleId IdType="pubmed">29366638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nayak SU, Griffiss JM, McKenzie R, Fuchs EJ, Jurao RA, An AT, Ahene A, Tomic M, Hendrix CW, Zenilman JM. 2014. Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. Antimicrob Agents Chemother
58:5047–5053. 10.1128/AAC.02830-14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.02830-14</ArticleId>
            <ArticleId IdType="pmc">PMC4135817</ArticleId>
            <ArticleId IdType="pubmed">24913160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snow DM, Riling K, Kimbler A, Espinoza Y, Wong D, Pham K, Martinez Z, Kraus CN, Conrad F, Garcia-Rodriguez C, Cobb RR, Marks JD, Tomic MT. 2019. Safety and pharmacokinetics of a four monoclonal antibody combination against botulinum C and D neurotoxins. Antimicrob Agents Chemother
63:e01270-19. 10.1128/AAC.01270-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.01270-19</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guptill JT, Raja SM, Juel VC, Walter EB, Cohen-Wolkowiez M, Hill H, Sendra E, Hauser B, Jackson P, Swamy GK. 2021. Safety, tolerability and pharmacokinetics of NTM-1632, a novel mixture of three monoclonal antibodies against botulinum toxin B. Antimicrob Agents Chemother
65:e02329-20. 10.1128/AAC.02329-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.02329-20</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA
99:11346–11350. 10.1073/pnas.172229899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.172229899</ArticleId>
            <ArticleId IdType="pmc">PMC123259</ArticleId>
            <ArticleId IdType="pubmed">12177434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pless DD, Torres ER, Reinke EK, Bavari S. 2001. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun
69:570–574. 10.1128/IAI.69.1.570-574.2001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/IAI.69.1.570-574.2001</ArticleId>
            <ArticleId IdType="pmc">PMC97921</ArticleId>
            <ArticleId IdType="pubmed">11119555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT. 2019. Pharmacokinetics of human recombinant anti-botulinum toxin antibodies in rats. Toxins
11:345. 10.3390/toxins11060345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11060345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD. 2019. Monoclonal antibody combinations prevent serotype A and serotype B inhalational botulism in a guinea pig model. Toxins (Basel)
11:208. 10.3390/toxins11040208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/toxins11040208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anonymous. 2017. BAT(R) [botulism antitoxin heptavalent (A, B, C, D, E, F, G) - (equine)] sterile solution for injection [package insert]. Cangene Corportation, Winnipeg, Manitoba (Canada).</Citation>
        </Reference>
        <Reference>
          <Citation>Ology Bioservices Incorporated. 2018. Investigational brochure: anti-BoNT E antibody (NTM-1633) treatment and prevention of type E botulism poisoning, version 1.0.
Ology Bioservices, Alameda, CA.</Citation>
        </Reference>
        <Reference>
          <Citation>NIAID. 2002. NIAID biodefense research agenda for CDC category A agents. U.S. Department of Health and Human Services, Washington, DC. http://sp.xoma.com/sites/RefLib/Library/niaid-2002.pdf.</Citation>
        </Reference>
        <Reference>
          <Citation>Barras V, Greub G. 2014. History of biological warfare and bioterrorism. Clin Microbiol Infect
20:497–502. 10.1111/1469-0691.12706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/1469-0691.12706</ArticleId>
            <ArticleId IdType="pubmed">24894605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD. 2012. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem
421:351–361. 10.1016/j.ab.2011.09.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ab.2011.09.030</ArticleId>
            <ArticleId IdType="pmc">PMC4209596</ArticleId>
            <ArticleId IdType="pubmed">22037290</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
